Loading clinical trials...
Loading clinical trials...
Showing 1-3 of 3 trials
NCT07524270
The goal of this clinical trial is to learn if a human equivalent lactoferrin supplement (effera®) can improve menstrual symptoms, mood, and quality of life in healthy women aged 18-40. The main questions it aims to answer are: Does effera® reduce the severity of menstrual symptoms? Does effera® improve mood, gastrointestinal symptoms, and overall well-being? Researchers will compare three different doses of effera® to a placebo (a look-alike supplement with no active ingredient) to see if the supplement improves these outcomes. Participants will: Take the assigned supplement (effera® or placebo) daily for 12 weeks Complete online questionnaires about menstrual symptoms, mood, and health Optionally share sleep and activity data from a wearable device
NCT07382947
The most common symptom that occurs during the menstrual cycle is cramping pain in the lower abdomen. This pain during the menstrual cycle is called dysmenorrhea. It is one of the most common causes of pelvic pain in women. Dysmenorrhea is categorized into two types: primary and secondary. Primary dysmenorrhea manifests as painful cramps during the menstrual period without a pelvic pathology. The pain can radiate to the lower back, pelvis, and upper thigh. Although the etiology of primary dysmenorrhea is not fully known, four main causes have been identified. The etiology of primary dysmenorrhea is endocrine causes, increased prostaglandin levels, increased uterine activity, and psychological causes. Among these factors, increased uterine contractions are thought to be particularly effective in causing the pain. Ischemia in the uterus, which occurs with increased contractions, is among the factors that increase the pain. Primary dysmenorrhea has a prevalence ranging from 45% to 95%. Secondary dysmenorrhea, on the other hand, results from underlying pathological causes such as endometriosis, adenomyosis, uterine fibroids, or pelvic infections. Common symptoms of dysmenorrhea include lower abdominal pain along with headache, numbness, sleep disturbances, depression, vomiting, tender breasts, nausea, diarrhea, and increased urine output.
NCT06965790
A large proportion of radiological CT examinations require the intravenous administration of iodine-containing X-ray contrast medium. According to current guidelines, the amount required for CT examinations in the (portal) venous phase is calculated on the basis of body weight (e.g. 0.2-0.4 g iodine/kg body weight), but a standardized application dose of the contrast agent is often also used. In earlier studies, the investigators found that the iodine contrast in vessels and organs achieved with a standardized amount of contrast agent differs significantly between women and men. On average, women showed around 10% higher iodine contrast than men of the same height and weight. The investigators attribute these differences to physiological, sex-specific differences in blood volume. For example, the blood volume of a woman 175 cm tall and weighing 75 kg is approx. 400 ml less than that of a man of the same height and weight (approx. 4.6 vs. 5.0 l, calculated according to Nadler). Taking blood volume into account, sex was no longer a significant influencing factor in a retrospective cohort (n=274). The investigators would now like to investigate these results in a prospective study. For this purpose, two groups of patients with a clinical indication for a contrast-enhanced CT scan in the venous phase will be compared: 1. control group with regular weight-adjusted (n = 200) 2. study group with dosing according to blood volume (n = 200). The hypothesis is that the application scheme adapted to the blood volume leads to a more homogeneous contrasting of women and men. In order to quantify this effect, the iodine contrast values of both groups will be quantitatively analyzed, taking into account other influencing variables (height, weight). The investigators hope that this approach will reduce or even eliminate the observed sex-specific differences. This would lead to a sex-equal contrast based on an individualized amount of contrast medium.